Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | CLK1 | P49759 | 9/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.41 |
| ▸ | EPHB3 | P54753 | 2/20 | 0.40 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3845576 | 0.84 | ADORA2A (0.45) | ADORA2ACLK1TGFBR1EPHB3MAP3K14 | |
| SCHEMBL26979552 | 0.84 | CLK1 (0.60) | ADORA2ACLK1TGFBR1EPHB3 | |
| SCHEMBL14108204 | 0.83 | FYN (0.47) | ADORA2ACLK1 | |
| SCHEMBL25157156 | 0.83 | TGFBR1 (0.52) | ADORA2ACLK1TGFBR1EPHB3MAP3K14 | |
| SCHEMBL4256851 | 0.81 | TGFBR1 (0.47) | CLK1TGFBR1EPHB3 | |
| SCHEMBL21387431 | 0.81 | ADORA2A (0.44) | ADORA2ACLK1TGFBR1EPHB3 | |
| SCHEMBL4256827 | 0.80 | TGFBR1 (0.47) | CLK1TGFBR1EPHB3CLK2DYRK1A | |
| SCHEMBL25421217 | 0.80 | CLK1 (0.52) | CLK1TGFBR1CLK2DYRK1ACLK4 | |
| SCHEMBL1614377 | 0.79 | ADORA2A (0.47) | ADORA2ACLK1TGFBR1EPHB3MAP3K14 | |
| SCHEMBL15639434 | 0.78 | PIK3CA (0.45) | ADORA2ACLK1TGFBR1EPHB3MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PI4KA, PIP4K2A | ADORA2A 771/4885CLK1 1144/4885TGFBR1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.